Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corp
(NQ:
SRRK
)
9.270
+0.280 (+3.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Scholar Rock Holding Corp
< Previous
1
2
3
4
Next >
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
November 10, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
November 09, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
November 08, 2022
From
Scholar Rock
Via
Business Wire
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
October 22, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
October 06, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
October 04, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
September 20, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
September 16, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
August 08, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
July 26, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
July 19, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
July 15, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
July 01, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces $205 Million Registered Direct Offering
June 17, 2022
From
Scholar Rock
Via
Business Wire
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
June 17, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
June 09, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
June 02, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
May 16, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
April 21, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
March 22, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 13, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
February 25, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
January 25, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
January 10, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
November 30, 2021
From
Scholar Rock
Via
Business Wire
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
November 12, 2021
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
November 09, 2021
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at Upcoming Healthcare Conferences
November 02, 2021
From
Scholar Rock
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.